——Patients with Crohn's disease, multiple myeloma and schizophrenia will have access to reimbursement in Shenzhen
(November 3, 2015, Shenzhen) The Human Resources and Social Security Administration of Shenzhen Municipality recently announced the implementation of Shenzhen’s supplementary medical insurance for major and critical diseases. Eleven drugs have been incorporated into the List of Drugs of Supplementary Medical Insurance for Major and Critical Diseases in Shenzhen, including Remicade® (Infliximab for Injection), Velcade® (Bortezomib for Injection) and Sustenna® (Paliperidone Palmitate Injection) from Xian Janssen Pharmaceutical Ltd.. The respective indications of these drugs – Crohn's disease, multiple myeloma and schizophrenia – are also covered in the disease categories for reimbursement by supplementary medical insurance for major and critical diseases in Shenzhen.
Crohn's disease, multiple myeloma and schizophrenia are diseases imposing a heavy disease burden on patients and their families. Crohn's disease is a chronic progressive disease that can involve the full-thickness gastrointestinal tract, with multi-segmental intestinal ulcers as the main clinical feature. Repeated episodes of diarrhea, abdominal pain, fever or rectal bleeding will cause physical and psychological effects of varying seriousness for patients.
Multiple myeloma is a malignant tumor of the blood system, and mainly occurs in the elderly. Public awareness of multiple myeloma is generally low, leading to delayed treatment and a poor prognosis. According to clinical practice, nearly two-thirds of patients are already in an advanced stage by the time of diagnosis. Therefore, experts advise patients to seek treatment at the hematology department when experiencing symptoms including bone pain, anemia, renal insufficiency, hypercalcemia and recurrent infections.
Schizophrenia is a recurrent, chronic and persistent disease, with onset mostly in young adults. Usually the patients experience slow onset, with disorders of thought, emotion, behavior and more. In these patients, recurrence of the disease and serious damage to the patient's ability to function socially and work can be caused by interruption of treatment.
The introduction of supplementary medical insurance for major and critical diseases in Shenzhen will effectively reduce the burden of high medical costs arising from serious illness, further alleviate poverty caused by disease, help patients to access sustained and effective treatment to prolong their lives and to improve quality of life, and bring benefits to tens of thousands of families.
It has been reported that from November 1st to 30th, insured persons will pay premiums of 20 yuan/person/year; 70% of the costs of using the 11 drugs found on the List of Drugs of Supplementary Medical Insurance for Major and Critical Diseases in Shenzhen, for the treatment of diseases including Crohn's disease, multiple myeloma and schizophrenia, will be reimbursed without a minimum payment; the limit for reimbursement by medical insurance for one person will be RMB 150,000 per year; and such standards will be implemented within two years (between July 1, 2015 to June 30, 2017).
For more information, please visit:
Notice: Implementation of Shenzhen’s supplementary medical insurance for major and critical diseases in Shenzhen
http://www.szhrss.gov.cn/qt/zfzxgzdt/201509/t20150928_3240611_13604.htm
Notice: About supplementary medical insurance fee for major and critical diseases in the year of 2015-2016
http://www.sz.gov.cn/rsj/qt/tzgg/201510/t20151030_3304598_15385.htm
List of Drugs of Supplementary Medical Insurance for Major and Critical Diseases in Shenzhen
http://www.szhrss.gov.cn/tzgg/201511/t20151102_3337662.htm